The Medical Drug Market and its Reforms

Carine Milcent

Post-Print from HAL

Abstract: China is the second largest pharmaceutical market in the world. This sector grew by 21.4% between 2002 and 2012. In OECD countries, spending on medical drugs accounted for approximately 17% of total health spending or 1.5% of gross domestic product (GDP) in 2009. That same year, spending on pharmaceutical products in China represented 43% of the total healthcare expenditure. Aware of the issue, the Chinese government has reacted. A limitation on the hospital mark-up on drugs has been implemented and a list of key drugs that are considered essential has been set up. Drugs on this list have to be accessible to everyone, with a regulated price to be kept as low as possible. To keep prices low, procurement is made through centralized bidding at provincial level, pharmaceutical companies delivering directly to medical facilities. Yet, in the field, the reality remains at times complex, with different ways to circumvent these constraints.

Date: 2018
Note: View the original document on HAL open archive server: https://shs.hal.science/halshs-01960382v1
References: Add references at CitEc
Citations:

Published in Carine Milcent. Health Reform in China: From Violence To Digital Healthcare, Palgrave Mac Millan; Springer International Publishing, pp.153 - 170, 2018, 978-3-319-69735-2. ⟨10.1007/978-3-319-69736-9_7⟩

Downloads: (external link)
https://shs.hal.science/halshs-01960382v1/document (application/pdf)

Related works:
Working Paper: The Medical Drug Market and its Reforms (2018)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:halshs-01960382

DOI: 10.1007/978-3-319-69736-9_7

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().